Breaking News

US FDA accepts BASF Pharma Solutions’ excipient

Excipients (inactive ingredients) such as the Soluplus branded excipient play a critical role in enabling the drug development process for poorly s...

Aptamer Group's new deal supports novel therapies

Since the publication of the group’s full year results, the company has signed deals with a number of companies related to the development of Optim...

Metrion Biosciences launches HTS capability

“The launch of our HTS capability adds another layer of depth to our ion channel drug discovery services and complements our automated and conventi...

What does 2023 hold for oral solid dosage forms?

Recipharm’s Uwe Hanenberg, Head of Product Development, Oral Solid Dose, and Maria Lundin-Johnson, Head of Formulation Development, explore the lat...

WuXi launches parenteral formulation manufacturing line

This expansion demonstrates the company’s continuous commitment to enhance its injectable drug product platform

Quotient Sciences announces manufacturing and clinical testing partnership

Emplicure is developing EMPLI03 as an oral buccal tablet with extended-release properties intended for the treatment of moderate to severe pain

Expanding capacity through collaboration

Michael Earl, Director of Pharmaceutical Services at Owen Mumford, and Steven Kaufman, Vice President for Drug Delivery Systems, Stevanato Group, t...

Inspiration from unexpected places

How pharmaceutical companies can learn from advances in nicotine delivery

Andelyn to manufacture gene therapy for infantile neuroaxonal dystrophy

The disease leads to neurodegeneration in the nervous system of patients accompanied by an inflammatory response and causes progressive loss of men...

Aptamer opens state-of-the-art laboratories in York, England

The new facilities will support the increased demand for Optimer technology

Increasing patient compliance with ion exchange excipient taste masking

With a significant number of individuals reporting that they find it difficult to swallow tablets or capsules, and more people admitting to not tak...

Manufacturing Chemist LIVE 2022 in review (part I)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and excit...

C4XD signs $402 million licence with AstraZeneca

C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single dig...

Enabling oligonucleotide therapeutics with precision targeting methods

Oligonucleotides are a rapidly growing class of therapeutics. This modality appears to offer highly favourable therapeutic characteristics such as...

Want print copies of Manufacturing Chemist delivered to your door?

Catch up with Manufacturing Chemist in print, at your leisure

Orodispersibles and minitablets: optimising patient compliance by improving the sensory properties with isomalt

Orally dispersible minitablets are a drug dosage form that can help to improve patient compliance among children and others who have difficulty swa...